

DRUG PROFILE

INTRANASAL STEROID USE IN CHILDEN

***Jeeson C Unni**
****Ranjit Baby Joseph**

Abstract: *Intranasal steroids are a group of topically acting agents that are used in various upper respiratory disease conditions with a background of respiratory allergy. Currently they are recommended as the first line agents in nasal allergy with minimal side effects. A review on the current management strategies of nasal allergy and available agents is discussed in this article.*

Keywords: *Intranasal steroids, Allergic rhinitis, Adenoid hypertrophy, Rhinosinusitis, Nasal polyp*

Points to Remember

- *Intranasal steroids are the drug of choice in allergic rhinitis.*
- *Other indications are recurrent rhinosinusitis, adenoidal hypertrophy and nasal polyps.*
- *Systemic side effects are minimal.*
- *Preferred drugs in children are fluticasone and mometasone.*
- *Evidence of long-term efficacy is limited but suggests that in many children maintenance therapy is needed if symptom-relief is to persist.*

References

1. Brunton SA, Fromer LM. Treatment options for the management of perennial allergic rhinitis, with a focus on intranasal corticosteroids. *South Med J* 2007; 100(7): 701-708.
2. Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. *J Allergy Clin Immunol* 1999; 104: 150-158.
3. Corren J. Intranasal corticosteroids for allergic rhinitis: How do different agents compare. *J Allergy Clin Immunol* 1999; 104: 144-149.
4. Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. *Am J Otolaryngol* 2008; 29(6): 403-413.
5. Benninger MS, Hadley JA, Osguthorpe JD, Marple BF, Leopold DA, Derebery MJ. Techniques of intranasal steroid use. *Otolaryngol Head Neck Surg* 2004; 130: 5-24.
6. Homer JJ, Raine CH. An endoscopic photographic comparison of nasal drug delivery by aqueous spray. *Clin Otolaryngol* 1998; 23: 560-563.
7. Therapeutic Guidelines Limited. *Therapeutic Guidelines: respiratory. Version 4.* West Melbourne: Therapeutic Guidelines Limited; 2009.
8. Benninger MS. Epistaxis and its relationship to handedness with use of intranasal steroid spray. *Ear Nose Throat J* 2008; 87: 463-465.
9. Scadding G, Durham S, Mirakian R, Jones NS, Leech SC, Farooque S. British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis. *Clin Exp Allergy* 2008; 38: 19-42.

* Editor-in-chief,
IAP Drug Formulary,

** Senior Specialist in Pediatrics,
Aster Medcity,
Kochi.
email: jeeson1955@gmail.com

10. Li H, Sha Q, Zuo K, Jiang H, Cheng L, Shi J. Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children. *ORL J Otolaryngol Relat Spec* 2009; 71: 50-55.
11. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? *J Laryngol Otol*. 2003; 117(11): 843–845.
12. Yawn B. Comparison of once-daily intranasal corticosteroids for the treatment of allergic rhinitis: are they all the same? *Med Gen Med* 2006; 8(1): 23.
13. Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. *Ann Allergy Asthma Immunol* 1998; 81: 478-518.
14. Paramesh H, Nagaraju K, Sukumaran TU, Agarkhedkar S, Bhakta S, Tilak R et al. Airway Diseases Education and Expertise (ADEX) in Pediatrics: Adaptation for Clinical Practice in India. *Indian Pediatr* 2016; 53(2): 154-158.
15. Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. *Methods Find Exp Clin Pharmacol* 2010; 32(9): 669-674.
16. Zhang L, Mendoza-Sassi RA, César JA, Chadha NK. Intranasal corticosteroids for nasal airway obstruction in children with moderate to severe adenoidal hypertrophy. *Cochrane Database Syst Rev* 2008; (3): CD006286. doi: 10.1002/14651858.CD006286.pub2.
17. Demainet JG, Goetz DW. Pediatric adenoidal hypertrophy and nasal airway obstruction: reduction with aqueous nasal beclomethasone. *Pediatrics* 1995; 95(3): 355-364.
18. Weber SA, Ferrai GF. Incidence and evolution of nasal polyps in children and adolescents with cystic fibrosis. *Braz J Otorhinolaryngol* 2008; 74(1): 16-20.
19. Mygind N, Lund V. Intranasal corticosteroids for nasal polyposis: biological rationale, efficacy, and safety. *Treat Respir Med* 2006; 5(2): 93-102.
20. Passli D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. *Multidiscip Respir Med* 2016; 11: 18. doi: 10.1186/s40248-016-0054-3. eCollection 2016.
21. Stern RC, Boat TF, Wood RE, Matthews LW, Doershuk CF. Treatment and prognosis of nasal polyps in cystic fibrosis. *Am J Dis Child* 1982; 136(12): 1067-1070.
22. Chong LY, Head K, Hopkins C, Philpott C, Schilder AG, Burton MJ. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. *Cochrane Database Syst Rev* 2016; 4:CD011996. doi: 10.1002/14651858.CD011996.pub2.
23. Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. *Am J Otolaryngol* 2008; 29(6): 403-413.
24. Passli D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. *Multidiscip Respir Med* 2016; 11: 18.
25. Zalmanovici TA, Yaphe J. Steroids for acute sinusitis in adults and children. *Cochrane Database Syst Rev* 2013; 12. Art. No.: CD005149. DOI: 10.1002/14651858.CD005149.pub4.